Heart failure outcomes with empagliflozin in patienets with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial investigators - Fitchett, D; Zinman, B; Wanner, C (Eur Heart J, 2016)
doi:10.1093/eurheartj/ehv728